@EbosLab

Associate Prof in Cancer Genetics @Roswellpark studying drug resistance, metastasis, microenvironment, immunecheckpoints, angiogenesis. See @ebos.bsky.social

 Buffalo, NY
roswellpark.org/research/labs/ebos-lab
Joined September 2014
  • Tweets454
  • Following919
  • Followers580
61Media
John Ebos retweeted
Nick Salgia@NickSalgiaOct 9
Great to see this fun side project from my 3rd year of med school @Jacobs_Med_UB @RoswellPark published in @jitcancer with #JasonMuhitch, #AnuragSingh, @waraonc23, etc, exploring impacts of SBRT on humoral immunity in mRCC: jitc.bmj.com/content/14/10/e… 1/6

Stereotactic body radiation therapy enriches mediators of humoral immune activity in metastatic...

Background Stereotactic body radiation therapy (SBRT) has recently been shown to be effective against renal cell carcinoma (RCC); ongoing clinical trials seek to assess the impact of SBRT on immune...

jitc.bmj.com
4
6
16
705
John Ebos retweeted
KidneyCAN
@kidneycanAug 18
Why is kidney cancer advocacy stronger when patients, clinicians, and researchers speak together? Dr. Jason Muhitch shares his perspective on the power of bringing these voices together in meetings with Congress and discusses the research from #KCRS26 that he believes has the greatest potential to change patient care. Watch the full conversation to hear his perspective on advocacy, collaboration, and the future of kidney cancer research. #AcceleratingCures
1
4
7
430
Phase III BR.31 results @JCO_ASCO - adjuvant durvalumab for resected NSCLC: no difference in DFS in the primary population PD-L1 ≥ 25% (HR 0.93) or any of the secondary populations. More inconsistency in the adjuvant setting in contrast to neoadjuvant. ascopubs.org/doi/10.1200/JCO…

Adjuvant Durvalumab in Completely Resected Early-Stage Non–Small Cell Lung Cancer

PURPOSEAdjuvant immunotherapy improved patient outcomes in two trials in completely resected non–small cell lung cancer (NSCLC), but with conflicting primary end point results. The Canadian Cancer...

ascopubs.org
21
4
75
11,117
Happy to share our @bioprotocolbyte describing an ex vivo splenocyte co-culture method to measure CD8+ T-cell function. This protocol was used in our recent papers published in @emboreports (2025) and @MCT_AACR (2024). bio-protocol.org/en/bpdetail…
1
3
201
Many thanks to Melissa Dolan for leading this effort and to Yuhao Shi, Amber McKenery, Stephanie Tzetzo, Kohei Chida, Kazuaki Takabe, and Scott Abrams for helping to get this together.
2
130
Cuts to cancer research funding at Department of Defense for 2025 fightcancer.org/sites/defaul…
2
2
260
Want to know what we do at Inria - Inserm COMPO ? Have a look at this blog post where I explain success stories of hashtag#mechanistic hashtag#learning to improve clinical oncology. mathematical-oncology.org/bl…
3
3
542
John Ebos retweeted
John Ebos@EbosLab11 Dec 2024
This work was the result of years of dedicated work and sacrifice by Yuhao (Tom) Shi @tshi42, a talented @UBuffaloMDPhDstudent in the @EbosLab who received F30 @NIHFunding from @NCICancerBio and is now doing his residency at NYU @NYULH_RadOnc. Congratulations Tom!
1
1
2
208
John Ebos retweeted
John Ebos@EbosLab11 Dec 2024
We found that the interferon-regulated secretory machinery in tumor cells is ‘rewired’ after acquired resistance to PD-L1 inhibition, altering the immune microenvironment and decreasing the tumor-killing ability of T cells. @RoswellPark #MedTwitter #Oncology #ImmunoOnc
1
4
1
3
2,025
📣New paper from our lab published in @emboreports: Acquired resistance to PD-L1 inhibition enhances a type I IFN-regulated secretory program in tumors @RoswellPark @ACS_Research @ACS_WNY @GeneticsRoswell #MedTwitter #Oncology #ImmunoOnc embopress.org/doi/full/10.10…
2
1
1
10
1,356
more replies
This work also could not have happened without Amber McKenery in @EbosLab, who drove this project in the final years. Thank you Amber! roswellpark.org/research/lab…
1
139
Finally, this work was only possible because of grants from the American Cancer Society, the Roswell Park Alliance Foundation, and the F30 NIH grant. Thank you! @RoswellPark @ACS_Research @ACS_WNY @AmericanCancer @NCICancerBio
1
165
Thrilled to share our story out in Cancer Cell, led by the amazing Kay Hanggi (now on the job market). We show that necrotic forms of cell death and the subsequent release of IL1a drives myeloid-based immune suppression in models of breast cancer. (1/11) cell.com/cancer-cell/abstrac…
7
21
2
118
8,959
Senescence as a therapeutic target in cancer and age-related diseases nature.com/articles/s41573-0… This new review evaluates the status of senotherapies, including senolytics, senomorphics, interventions that mitigate senescence and strategies that harness the immune system
2
57
1
176
14,885
SuperPlots: Communicating reproducibility and variability in cell biology | Journal of Cell Biology | Rockefeller University Press rupress.org/jcb/article/219/…

SuperPlots: Communicating reproducibility and variability in cell biology

This Viewpoint proposes a simple way to highlight both experimental reproducibility and cell-to-cell variation, while avoiding pitfalls common in analysis

rupress.org
1
136
Spatial Architecture of Single-cell and Vasculature in Tumor Microenvironment... sciencedirect.com/science/ar…
134
Landscape of subsequent therapies in perioperative immunotherapy trials across multiple cancer types - The Lancet Oncology thelancet.com/journals/lanon…
94
Angiogenic and Immune Predictors of Neoadjuvant Axitinib Response in Renal Cell Carcinoma with Venous Tumour Thrombus biorxiv.org/content/10.1101/…

Angiogenic and Immune Predictors of Neoadjuvant Axitinib Response in Renal Cell Carcinoma with...

Venous tumour thrombus (VTT), where the primary tumour invades the renal vein and inferior vena cava, affects 10-15% of renal cell carcinoma (RCC) patients. Curative surgery for VTT is high-risk, but...

biorxiv.org
109
Load more